{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "30075951",
  "DateCompleted": {
    "Year": "2018",
    "Month": "09",
    "Day": "27"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "09",
    "Day": "27"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2018",
        "Month": "07",
        "Day": "31"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.lpm.2018.01.026",
      "S0755-4982(18)30290-2"
    ],
    "Journal": {
      "ISSN": "2213-0276",
      "JournalIssue": {
        "Volume": "47",
        "Issue": "7-8 Pt 1",
        "PubDate": {
          "Year": "2018",
          "Season": "Jul-Aug"
        }
      },
      "Title": "Presse medicale (Paris, France : 1983)",
      "ISOAbbreviation": "Presse Med"
    },
    "ArticleTitle": "Screening cancer after venous thromboembolism: How many abnormal tests before diagnosing cancer? An analysis of practice.",
    "Pagination": {
      "StartPage": "e99",
      "EndPage": "e106",
      "MedlinePgn": "e99-e106"
    },
    "Abstract": {
      "AbstractText": [
        "Since Trousseau, we knows that venous thrombemboembolism (VTE) can reveal occult cancer. Different strategies of cancer screening have been evaluated: they are often time-consuming, cause stress and anxiety, and frequently require second-look examinations (due to the risk of false positives), with ultimately a very low yield (about 5%). We evaluated the number of suspect cancer tests before reporting them to the number of cancers finally diagnosed, after a VTE, in the setting of practice's analysis.",
        "We studied retrospectively patients hospitalized for a VTE and with a cancer screening, between 2011 and 2012. Screening cancer was defined by performing at least one of the following tests: PSA, fecal occult blood test, mammography, abdominopelvic iconography (abdominal ultrasound and/or abdominal CT scan). We recorded the suspected cancer tests, the cancers diagnosed, their stage and the survival. These results were expressed as a percentage with a 95% confidence interval.",
        "Out of the 491 patients treated for a VTE, screening cancer was performed on 295 patients (median age 66.2 years). Nineteen PSA (16.7%, 95% CI [10.3-25]) were abnormal, with 2 localized prostate cancers. Nineteen fecal occult blood tests (15.3%, 95% CI [9.5-23]) were positive, with 2 local cancers. Five mammograms suspected cancer (4.7% 95% CI [1.6-10.8]) for one confirmed. Thirty-eight abdomino-pelvic iconographies (14.4% 95% CI [10.4-19.2]) were suspect, with 7 confirmed cancers, 6 being metastatic at times of diagnostic.",
        "Among the 607 tests performed, 81 were suspected of cancer (13.3%) for only 12 cancers confirmed (2.0%). Screening cancer exposes patients to several false positive tests."
      ],
      "CopyrightInformation": "Copyright \u00a9 2018 Elsevier Masson SAS. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHU de St-\u00c9tienne, h\u00f4pital Nord, service de m\u00e9decine vasculaire et th\u00e9rapeutique, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France. Electronic address: cecile.duvillard@chu-St-\u00c9tienne.fr."
          }
        ],
        "LastName": "Duvillard",
        "ForeName": "C\u00e9cile",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHU de St-\u00c9tienne, h\u00f4pital Nord, service de m\u00e9decine vasculaire et th\u00e9rapeutique, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France; Inserm, CHU de St-\u00c9tienne, centre d'investigation clinique CIC 1401, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France."
          }
        ],
        "LastName": "De Magalhaes",
        "ForeName": "Elodie",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHU de St-\u00c9tienne, h\u00f4pital Nord, service de m\u00e9decine vasculaire et th\u00e9rapeutique, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France."
          }
        ],
        "LastName": "Moulin",
        "ForeName": "Nathalie",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHU de St-\u00c9tienne, h\u00f4pital Nord, service de m\u00e9decine vasculaire et th\u00e9rapeutique, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France; Inserm, CHU de St-\u00c9tienne, centre d'investigation clinique CIC 1401, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France."
          }
        ],
        "LastName": "Accassat",
        "ForeName": "Sandrine",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHU de St-\u00c9tienne, h\u00f4pital Nord, service de m\u00e9decine vasculaire et th\u00e9rapeutique, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France; Inserm, CHU de St-\u00c9tienne, centre d'investigation clinique CIC 1401, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France; Inserm, Campus sant\u00e9 innovation, UMR 1059 SAINBIOSE, \u00e9quipe dysfonctions vasculaires et h\u00e9mostase, 10, rue de la Marandi\u00e8re, 42270 St-Priest-en-Jarez, France."
          }
        ],
        "LastName": "Mismetti",
        "ForeName": "Patrick",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "CHU de St-\u00c9tienne, h\u00f4pital Nord, service de m\u00e9decine vasculaire et th\u00e9rapeutique, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France; Inserm, CHU de St-\u00c9tienne, centre d'investigation clinique CIC 1401, avenue Albert-Raimond, 42055 St-\u00c9tienne cedex, France; Inserm, Campus sant\u00e9 innovation, UMR 1059 SAINBIOSE, \u00e9quipe dysfonctions vasculaires et h\u00e9mostase, 10, rue de la Marandi\u00e8re, 42270 St-Priest-en-Jarez, France."
          }
        ],
        "LastName": "Bertoletti",
        "ForeName": "Laurent",
        "Initials": "L"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Presse Med",
    "NlmUniqueID": "8302490",
    "ISSNLinking": "0755-4982"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged, 80 and over"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Early Detection of Cancer"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "complications",
        "diagnosis",
        "mortality"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Retrospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Survival Rate"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Venous Thromboembolism"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Young Adult"
    }
  ]
}